Research map: Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide

Back to the article

Papers in this map

  1. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis · Paschalis Karakasis · 2024 · 205 citations · Cited by this paper
  2. Postpartum Body Composition and Early Breastfeeding Behaviours in Women With Gestational Diabetes Mellitus: A Case‐Control Study · 2026 · Related
  3. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions · Areesha Moiz · 2025 · 139 citations · Cited by this paper
  4. Retinol, Carotenoid, and Tocopherol Intake and Status, and the Risk of Islet Autoimmunity and Type 1 Diabetes: The Environmental Determinants of Diabetes in the Young Study · 2026 · Related
  5. Obesity and Diabetic Complications: A Study from the Nationwide Diabetes Report of the National Program for Prevention and Control of Diabetes (NPPCD-2021) Implications for Action on Multiple Scales · Fatemeh Moosaie · 2022 · 37 citations · Cited by this paper
  6. Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety · 2026 · Related
  7. Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis · Kaixin Duan · 2022 · 34 citations · Cited by this paper
  8. Assessment of Diabetes Risk in Patients With Hepatitis B: A Machine Learning Approach Integrating 11 Inflammatory and Immune Indicators · 2026 · Related
  9. The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: A meta-analysis of randomised controlled trials · Fupeng Liu · 2022 · 28 citations · Cited by this paper
  10. Diabetic Foot Ulcer Prevention Priorities Established by Consumers From Low Socioeconomic and Culturally Diverse Communities · 2026 · Related
  11. Bone Response to Weight Loss Following Bariatric Surgery · Chiara Mele · 2022 · 27 citations · Cited by this paper
  12. Gene‐Lifestyle Interplay in Type 1 Diabetes: Joint Effects and Interactions From Cross‐Sectional and Longitudinal Cohort Analyses · 2026 · Related
  13. New Insights into Calorie Restriction Induced Bone Loss · Linyi Liu · 2023 · 25 citations · Cited by this paper
  14. Changes in Brain Volumetric Measures Associated With Type 1 Diabetes Depict an Evolutionary Adaptation Process to Developmental Cognitive Demands · 2026 · Related
  15. GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes · Tien‐Hsing Chen · 2025 · 21 citations · Cited by this paper
  16. Network and Pairwise Meta‐Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus · 2026 · Related
  17. Effects of short‐acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes · Nicklas Järvelä Johansen · 2021 · 20 citations · Cited by this paper
  18. Global Trends and Inequalities in Diabetes Prevalence and Treatment Coverage Among Adults Aged ≥ 45 Years, 1990–2040: Insights From the NCD‐RisC Database · 2026 · Related
  19. Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes · Ebaa Al‐Ozairi · 2023 · 20 citations · Cited by this paper
  20. Disordered Eating Behaviours and Associated Factors Among People With Type 1 Diabetes: A Cross‐Sectional Study in Spain—D1ANAS Project · 2026 · Related
  21. Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis · Hee‐Ju Kim · 2024 · 18 citations · Cited by this paper
  22. The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials · Jiangting Lu · 2025 · 18 citations · Cited by this paper
  23. Prevalence of obesity in people with and without type 1 diabetes across Belgium, Kuwait, and Mexico: an IMI2 SOPHIA study · Ebaa Al‐Ozairi · 2024 · 15 citations · Cited by this paper
  24. Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide · Ebaa Al‐Ozairi · 2025 · 12 citations · Cited by this paper
  25. Visceral Adiposity as an Independent Risk Factor for Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus: A Retrospective Study · Rui-Ling Wu · 2024 · 9 citations · Cited by this paper
  26. Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis · Amanda R. Purcell · 2025 · 9 citations · Cited by this paper
  27. From obesity to cardiovascular disease: pathological basis and clinical implications · Matteo Nardin · 2026 · 5 citations · Cited by this paper
  28. Abstract #1912894 Overweight and Obesity Among People With Type 1 Diabetes: Prevalence and Associated Factors · Mohammad A. Irshad · 2024 · 2 citations · Cited by this paper
  29. Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m2, and chronic kidney disease – A randomised, controlled pilot study · Ebaa Al Ozairi · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)